Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: a double-blind, randomized, crossover trial.

Pasqua MR, Tsoukas MA, Kobayati A, Aboznadah W, Jafar A, Haidar A

Nature medicine10 Jan 2025Cited by 55 (Europe PMC)

PMID39794615PMCIDPMC12003151DOI10.1038/s41591-024-03463-zPepBankPUB-39794615

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with type 1 diabetes using automated insulin delivery, semaglutide increased time in the target glucose range by a mean 4.8 percentage points versus placebo.
In plain wordsIn adults with type 1 diabetes using automated insulin delivery, semaglutide raised the time in target glucose range more than placebo did.
Peptide
Semaglutide
Outcome
IncreaseTime in target glucose range 3.9-10.0 mmol/l
Study
n = 24
Comparator
Placebo
Analysis
Primary
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 1 mg or maximum tolerated dose · subcutaneous · 11 weeks titration followed by 4 weeksAs given in this study (human).
Measurements
Time in range difference
4.8 percentage points
semaglutide vs placebo
Source sentences
Summary
Compared to placebo, semaglutide increased time in the target range by a mean 4.8 (s.d. = 7.6) percentage points (P = 0.006)
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a randomized, double-blind, crossover trial to assess semaglutide as adjunct to automated insulin delivery therapy in adults with type 1 diabetes.
Report a problemFND-3979461501
02HumanRandomized controlled trialSafety outcome
In adults with type 1 diabetes using automated insulin delivery, semaglutide did not increase time spent below 3.9 mmol/l versus placebo.
In plain wordsIn adults with type 1 diabetes, semaglutide did not increase the time spent with low glucose compared with placebo.
Peptide
Semaglutide
Outcome
No significant changeTime below 3.9 mmol/l
Study
n = 24
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 1 mg or maximum tolerated dose · subcutaneous · 11 weeks titration followed by 4 weeksAs given in this study (human).
Source sentences
Summary
without increasing the time spent below 3.9 mmol l^-1 (P = 0.19)
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a randomized, double-blind, crossover trial to assess semaglutide as adjunct to automated insulin delivery therapy in adults with type 1 diabetes.
Report a problemFND-3979461502
03HumanRandomized controlled trialSafety outcome
In adults with type 1 diabetes using automated insulin delivery, semaglutide did not increase time spent below 3.0 mmol/l versus placebo.
In plain wordsIn adults with type 1 diabetes, semaglutide did not increase the time spent with very low glucose compared with placebo.
Peptide
Semaglutide
Outcome
No significant changeTime below 3.0 mmol/l
Study
n = 24
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
up to 1 mg or maximum tolerated dose · subcutaneous · 11 weeks titration followed by 4 weeksAs given in this study (human).
Source sentences
Summary
or below 3.0 mmol l^-1 (P = 0.65)
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a randomized, double-blind, crossover trial to assess semaglutide as adjunct to automated insulin delivery therapy in adults with type 1 diabetes.
Report a problemFND-3979461503
04HumanRandomized controlled trialSafety outcome
In adults with type 1 diabetes using automated insulin delivery, two episodes of recurrent euglycemic ketosis without acidosis occurred during semaglutide use.
In plain wordsIn adults with type 1 diabetes, two episodes of ketosis without acidosis occurred during semaglutide use.
Peptide
Semaglutide
Outcome
Not applicableRecurrent euglycemic ketosis without acidosis
Study
n: not reported in source
Outcome group
Adverse events · Metabolic and weight
Studied dose
up to 1 mg or maximum tolerated dose · subcutaneous · 11 weeks titration followed by 4 weeksAs given in this study (human).
Source sentences
Summary
there were two episodes of recurrent euglycemic ketosis without acidosis during semaglutide use.
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a randomized, double-blind, crossover trial to assess semaglutide as adjunct to automated insulin delivery therapy in adults with type 1 diabetes.
Report a problemFND-3979461504
05HumanRandomized controlled trialSafety outcome
In adults with type 1 diabetes using automated insulin delivery, no diabetic ketoacidosis occurred during any intervention, semaglutide included.
In plain wordsIn adults with type 1 diabetes, no diabetic ketoacidosis occurred in either the semaglutide or the placebo period.
Peptide
Semaglutide
Outcome
No significant changeDiabetic ketoacidosis
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
up to 1 mg or maximum tolerated dose · subcutaneous · 11 weeks titration followed by 4 weeksAs given in this study (human).
Source sentences
Summary
While no diabetic ketoacidosis or severe hypoglycemia occurred during any of the interventions
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a randomized, double-blind, crossover trial to assess semaglutide as adjunct to automated insulin delivery therapy in adults with type 1 diabetes.
Report a problemFND-3979461505
06HumanRandomized controlled trialSafety outcome
In adults with type 1 diabetes using automated insulin delivery, no severe hypoglycemia occurred during any intervention, semaglutide included.
In plain wordsIn adults with type 1 diabetes, no severe low blood sugar occurred in either the semaglutide or the placebo period.
Peptide
Semaglutide
Outcome
No significant changeSevere hypoglycemia
Study
n: not reported in source
Comparator
Placebo
Outcome group
Adverse events · Metabolic and weight
Studied dose
up to 1 mg or maximum tolerated dose · subcutaneous · 11 weeks titration followed by 4 weeksAs given in this study (human).
Source sentences
Summary
While no diabetic ketoacidosis or severe hypoglycemia occurred during any of the interventions
1 context sentence(design, population, supporting numbers)
Summary · context
We performed a randomized, double-blind, crossover trial to assess semaglutide as adjunct to automated insulin delivery therapy in adults with type 1 diabetes.
Report a problemFND-3979461506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials2

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

2 trials · 1 ongoing · 1 completed · source ClinicalTrials.gov (opens in a new tab)

RecruitingPhase 2/3NCT07284511

A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar

McGill University Health Centre/Research Institute of the McGill University Health Centren = 10519 May 2026 to est. Jan 2029

Type 1 Diabetes · Type 1 Diabetes Mellitus · T1D · T1DM · T1DM - Type 1 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 27 May 2026

CompletedPhase 2/3NCT05205928

Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care

McGill University Health Centre/Research Institute of the McGill University Health Centren = 282 Oct 2022 to 30 Jun 2024

Type 1 Diabetes · Diabetes Mellitus, Type 1

Trial page ClinicalTrials.govUpdated 22 Jan 2025

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.